Related Experiment Videos
[Fetal-neonatal thrombocytopenia of immunologic origin: current aspects]
C Kaplan1, M C Morel-Kopp, F Forestier
1Institut National de Transfusion Sanguine, Service d'Immunologie Leuco-Plaquettaire, Paris, France.
Insights
Fetal/neonatal immune thrombocytopenias stem from maternal antibodies destroying fetal platelets, risking intracerebral hemorrhage. Fetal blood sampling is crucial for assessing status, as maternal factors are not predictive.
Area of Science:
- Perinatology
- Immunology
- Hematology
Context:
- Fetal/neonatal immune thrombocytopenias are caused by maternal antiplatelet antibodies leading to increased platelet destruction.
- This condition poses a risk of intracerebral hemorrhage, potentially causing neurological impairment or death.
- Defective platelet function can exacerbate these risks.
Purpose:
- To highlight the diagnostic challenges in fetal/neonatal immune thrombocytopenias.
- To emphasize the importance of fetal blood sampling for accurate fetal status assessment.
- To discuss the effectiveness of antenatal therapies in specific cases and the need for further research.
Summary:
- Maternal antiplatelet antibodies cause fetal/neonatal immune thrombocytopenias, increasing the risk of intracerebral hemorrhage and neurological damage.
- No maternal parameter predicts fetal platelet count; fetal blood sampling is the sole reliable assessment method.
- Antenatal therapy is effective only in materno-fetal alloimmunisation, with optimal treatment strategies still under investigation.
Impact:
- Distinguishing between auto- and allo-immune thrombocytopenia is critical for appropriate neonatal management and future pregnancy care.
- Developing a routine screening program for high-risk pregnancies is essential.
- Improved understanding and management can reduce fetal mortality and long-term neurological sequelae.
Abstract:
Fetal/neonatal immune thrombocytopenias result from increased platelet destruction by maternal antiplatelet antibodies. There is a risk of intracerebral haemorrhage and therefore of neurological impairment or death during the thrombocytopenic period, especially if a defective platelet function co-exists. As no maternal parameter is predictive of the fetal platelet count, the only reliable assessment of the fetal status depends on the fetal blood sampling. Only in case of materno-fetal alloimmunisation the therapy initiated to reverse fetal thrombocytopenia was shown to be effective, but the optimal mode of antenatal treatment is currently under study. As the neonatal therapy and the management of subsequent pregnancies are somehow different it is mandatory to make the distinction between the auto or allo-origin of the fetal thrombocytopenia. The definition of high risk pregnancies will be of help for the development of a routine screening program.